HC Wainwright Estimates FibroGen FY2026 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Investment analysts at HC Wainwright issued their FY2026 EPS estimates for FibroGen in a report issued on Tuesday, December 17th. HC Wainwright analyst M. Keller anticipates that the biopharmaceutical company will post earnings of ($0.56) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for FibroGen’s FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.44) EPS.

Several other equities research analysts have also weighed in on FGEN. William Blair restated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. StockNews.com assumed coverage on FibroGen in a research report on Monday. They set a “hold” rating for the company.

FibroGen Stock Performance

FibroGen stock opened at $0.34 on Wednesday. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.93. The stock’s 50 day simple moving average is $0.35 and its two-hundred day simple moving average is $0.57. The stock has a market cap of $34.51 million, a price-to-earnings ratio of -0.28 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the prior year, the firm earned ($0.52) EPS.

Hedge Funds Weigh In On FibroGen

A number of institutional investors and hedge funds have recently made changes to their positions in FGEN. Geode Capital Management LLC grew its stake in shares of FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 32,884 shares during the last quarter. FMR LLC boosted its holdings in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of FibroGen in the third quarter worth $307,000. Point72 DIFC Ltd increased its holdings in shares of FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 280,161 shares in the last quarter. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.